Table 2.
Information about vaccination in the study groups
| Behçet’s syndrome, n = 256 | Familial Mediterranean fever, n = 247 | Rheumatic diseases, n = 601 | p | |
|---|---|---|---|---|
| Vaccine type, n (%) | < 0.001 | |||
| CoronaVac | 109 (42.6) | 90 (36.4) | 343 (57.1) | |
| BioNTech | 147 (57.4) | 157 (63.6) | 258 (42.9) | |
| Vaccine dose, n (%) | < 0.001 | |||
| Single shot | 13 (5.1) | 19 (7.7) | 83 (13.8) | |
| Double shots | 243 (94.9) | 228 (92.3) | 518 (86.2) | |
| Days passed since last dose, mean ± SD, years | 87.10 ± 43.82 | 80.22 ± 49.75 | 77.38 ± 44.74 | < 0.001 |
| Post-vaccine COVID-19, n (%) | ||||
| CoronaVac | 11 (10.1) | 11 (12.2) | 22 (6.4) | 0.140 |
| BioNTech | 2 (1.4) | 5 (3.2) | 7 (2.7) | 0.566 |